



- 200(8):957–965.
9. Saito S, Takeda Y, Sakai M, Nakabayashi M, Hayakawa S. The incidence of pre-eclampsia among couples consisting of Japanese women and Caucasian men. *J Reprod Immunol*. 2006;70(1–2):93–98.
 10. Hiby SE, et al. Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2. *J Clin Invest*. 2010;120(11):4102–4110.
 11. Tam LS, Gu J, Yu D. Pathogenesis of ankylosing spondylitis. *Nat Rev Rheumatol*. 2010;6(7):399–405.
 12. Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. *Curr Opin Allergy Clin Immunol*. 2007;7(4):317–323.
 13. Mandelboim O, et al. Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. *J Exp Med*. 1996;184(3):913–922.
 14. Parham P. MHC class I molecules and KIRs in human history, health and survival. *Nat Rev Immunol*. 2005;5(3):201–214.
 15. Moesta AK, Graef T, Abi-Rached L, Older Aguilar AM, Guethein LA, Parham P. Humans differ from other hominids in lacking an activating NK cell receptor that recognizes the C1 epitope of MHC class I. *J Immunol*. 2010;185(7):4233–4237.
 16. Barclay AN, Hatherley D. The counterbalance theory for evolution and function of paired receptors. *Immunity*. 2008;29(5):675–678.
 17. Anfossi N, et al. Human NK cell education by inhibitory receptors for MHC class I. *Immunity*. 2006;25(2):331–342.
 18. Fauriat C, Ivarsson MA, Ljunggren HG, Malmberg KJ, Michaëlsson J. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. *Blood*. 2009;115(6):1166–1174.
 19. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. *Lancet*. 2005;365(9461):785–799.
 20. Single RM, et al. Global diversity and evidence for coevolution of KIR and HLA. *Nat Genet*. 2007;39(9):1114–1119.
 21. Gendzekhadze K, et al. Co-evolution of KIR2DL3 with HLA-C in a human population retaining minimal essential diversity of KIR and HLA class I ligands. *Proc Natl Acad Sci USA*. 2009;106(44):18692–18697.
 22. Duley L. The global impact of pre-eclampsia and eclampsia. *Semin Perinatol*. 2009;33(3):130–137.

WT1: a weak spot in KRAS-induced transformation

Silvia Licciulli and Joseph L. Kissil

Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania, USA.

Activating mutations in the *Ras* alleles are found frequently in tumors, making the proteins they encode highly attractive candidate therapeutic targets. However, *Ras* proteins have proven difficult to target directly. Recent approaches have therefore focused on identifying indirect targets to inhibit *Ras*-induced oncogenesis. For example, RNAi-based negative selection screens to identify genes that when silenced in concert with activating *Ras* mutations are incompatible with cellular proliferation, a concept known as synthetic lethality. In this issue of the *JCI*, Vicent et al. report on the identification of Wilms tumor 1 (*Wt1*) as a *Kras* synthetic-lethal gene in a mouse model of lung adenocarcinoma. Silencing of *Wt1* in cells expressing an endogenous allele of activated *Kras* triggers senescence in vitro and has an impact on tumor progression in vivo. These findings are of significant interest given previous studies suggesting that the ability of oncogenic *Kras* to induce senescence versus proliferation depends on its levels of expression.

Activating mutations in the *Ras* genes (*KRAS*, *HRAS*, and *NRAS*) are a common occurrence in a broad spectrum of tumors (1). It is therefore not surprising that extensive efforts have been made to develop therapies to directly target oncogenic *Ras*. However, the *Ras* proteins have proven to be formidable foes, and success with direct targeting approaches has been limited so far. One strategy to circumvent this issue has been to search for targets that could serve as a potential Achilles' heel to be exploited to have an impact on *Ras* indirectly. This approach is based on the idea that expression of oncogenic *Ras* results in tumor cell alterations so that they become dependent on one or more pathways or particular molecular targets, which then

represent ideal hits to strike the tumor cells while sparing normal cells (2). The concept of synthetic lethality perfectly fits this idea. Synthetic lethality between two genes occurs when loss of function of one gene results in cell death only in the presence of genetic alteration of the other, while mutation of either gene alone is compatible with viability. Several genes and pathways have been identified by this approach and, interestingly, many of these are not oncogenic themselves but become essential for cells in the tumorigenic state (see below for discussion of specific examples). It is thus clear why a gene that exhibits a synthetic-lethal interaction with activated *Ras* would represent a high-value target for the development of therapeutics. In this issue of the *JCI*, Vicent et al. describe the identification of Wilms tumor 1 (*Wt1*) as a novel synthetic-lethal gene in a mouse model of *Kras*-induced tumorigenesis in the lung (3).


Negative selection screens to identify *Ras* synthetic-lethal interactors

In the past, synthetic-lethal interactions have been largely studied in model organisms such as yeast, *Drosophila melanogaster*, and *Caenorhabditis elegans*. More recently, thanks to the development of RNAi technology (4–6), it has become feasible to extend the concept of synthetic lethality to mammalian cells to identify genes whose loss of function causes growth arrest or cell death (negative selection). Furthermore, the employment of systematic high-throughput platforms has allowed for screening of significant numbers of targets within a relatively short period of time and in an unbiased manner. In the case of *Ras*, after knocking down one or more specific targets, it is possible to evaluate the effects on viability through side-by-side comparison of cells with and without oncogenic *Ras* expression. However, the limitations of these approaches should also be noted. For example, the response to the inhibition of any given target will be highly dependent on multiple factors including cell type and screen conditions. Furthermore, to achieve a strong signal-to-background ratio and to control for off-target effects related to RNAi approaches, the experimental conditions of the screening require careful optimization (7). Nevertheless, the power of such approaches has been demonstrated recently by a number of studies (8–10).

Negative selection screens can be conducted using a well-by-well array or a

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: *J Clin Invest*. 2010; 120(11):3804–3807. doi:10.1172/JCI44901.

**Figure 1**

Negative selection shRNA screening approaches: single-well format versus pooled libraries. **(A)** In single-well arrays, shRNAs are transduced at 1 per well. Negative effect on growth and survival is evaluated individually by direct comparison of corresponding wells in different plates containing *Kras* wild-type (reference) and *Kras* mutant cells. **(B)** Pooled screens are conducted by infecting *Kras* wild-type (reference) and *Kras* mutant cells with an shRNA library. The cell populations are then selected either in vitro or in vivo, resulting in shRNAs with unfavorable effects on viability being depleted from the pool of cells. The depleted shRNAs are then identified through bar code tags.

pooled approach (Figure 1). In the well-by-well array, the impact of each shRNA on cell growth and survival is scored individually, requiring a high-throughput platform to perform the screen (Figure 1A). A successful example of this approach is the work of Scholl et al. (10), which led to the identification of serine/threonine kinase 33 (STK33), a kinase not previously known to be associated with cancer, as a *Kras* synthetic lethal. An shRNA library targeting approximately 1,000 genes encoding the majority of known and predicted protein kinases, selected phosphatases, and other known cancer-related targets was screened across a panel of *Kras* wild-type and mutant human cancer cell lines. Interestingly, STK33 is thought to function in this context by regulating the activity of the cell death agonist BCL2-associated agonist of cell death (BAD) (10). This work is an elegant example of the power of synthetic lethality screens; STK33, indeed, was not known as a component of the *Kras* signaling pathway and does not behave as an oncogene in transformation assays;

therefore, its role in *Kras* tumorigenesis would have been difficult to unveil by other approaches.

Another arrayed-format screen, which underscored the importance of the NF- κ B pathway as a critical effector of Ras signaling, revealed the dependence on TANK-binding kinase 1 (TBK1) for the survival of cells harboring activating *Kras* mutations (8). TBK1 is a noncanonical I κ B kinase and regulates innate immunity through activation of NF- κ B, interferon regulatory factor 3 (IRF3), and IRF7 (11). According to the report by Barbie et al., in the context of oncogenic *Kras*-driven lung tumorigenesis, TBK1 preferentially activates the NF- κ B pathway rather than the interferon response and loss of TBK1 ultimately results in inhibition of antiapoptotic signaling (8).

An alternative strategy for negative selection RNAi screening is the pooled approach, in which a bulk population of cells is infected with an entire pooled shRNA library at a low multiplicity of infec-

tion and selected for loss of viability either in vitro or upon implantation into mice (Figure 1B). shRNAs that are selectively eliminated from the pool can then be identified through “bar codes.” This approach allows for rapid evaluation of large, virtually genome-wide gene sets and for the identification of pathways and classes of genes rather than single candidates. An interesting example is the identification of mitotic genes such as polo-like kinase 1 (*PLK1*) and adenomatous polyposis coli (*APC*) as *Kras* synthetic lethals (9). Luo et al. propose that activated *Kras* subjects the cells to mitotic stress so that they require certain mitotic effectors to progress through mitosis (9). In the absence of these factors, mitosis is stalled or arrested, leading to cell death.

Identification of *Wt1* as a regulator of senescence and proliferation downstream of *Kras*

In this issue of the *JCI*, Vicent et al. report on their performance of a pooled negative selection shRNA screen to interrogate a



Table 1
Synthetic-lethal interaction between *Wt1* and oncogenic *Kras*

<i>Ras</i> status	<i>Wt1</i> status	MEF phenotype	NSCLC phenotype
Wild type	Wild type	Viable: normal proliferation	Viable: normal proliferation
Wild type	Deleted	Viable: normal proliferation	Viable: minimal decrease in cell viability, minimal decrease in BrdU uptake, no apoptosis
Mutant	Wild type	Viable: hyperproliferation	Viable: normal proliferation
Mutant	Deleted	Lethal: reduced proliferation, decreased S phase, decreased phospho-histone H3, senescence associated (SA- β gal), no apoptosis	Lethal: reduced proliferation, decreased BrdU incorporation, senescence (SA- β gal), no apoptosis

library focused on targets that had been previously implicated in non-small cell lung carcinoma (NSCLC) and/or downstream of *Kras* (3). The study was performed in cell lines derived from tumors that develop in an endogenous mouse model of *Kras*-driven lung adenocarcinoma. The list of top-scoring genes obtained from this primary screen was validated in a secondary screen in primary mouse embryo fibroblasts (MEFs) expressing either wild-type or oncogenic *Kras*. Of the targets validated, the authors focused on *Wt1*, a potential transcriptional regulator of the *Kras* signature.

The authors went on to validate the synthetic-lethal interaction between *Kras* and *Wt1* at multiple levels (3). First, they demonstrated that the effect of *Wt1* loss was specific to oncogenic *Kras*-expressing cells by repeating the secondary screen in a mouse lung epithelial cell line expressing wild-type *Kras*. Moreover, they showed that loss of *Wt1* reduced the tumorigenicity of a *Kras*-mutant lung tumor cell line in a xenograft model and provided strong genetic evidence of the functional interaction between *Kras* and *Wt1* through the employment of a mouse model harboring a conditionally expressed oncogenic allele of *Kras* combined with a conditional knock-out allele of *Wt1*. MEFs derived from these animals displayed a cell-cycle distribution compatible with an antiproliferative effect of *Wt1* loss, specifically in oncogenic *Kras*-expressing cells (Table 1). Finally, the loss of *Wt1* in an endogenous model of *Kras*-induced lung adenocarcinoma resulted in decreased tumor burden compared with mice expressing *Wt1*, confirming the requirement for *Wt1* in *Kras*-driven lung tumorigenesis.

Wt1 was originally identified as a tumor suppressor in Wilms tumor (12). It is a zinc-finger transcription factor expressed as multiple splice forms and has been

shown to have either tumor suppressive or oncogenic functions in a manner that appears to be cell-type and context dependent (13). Considering that *Wt1* functions as a transcription factor, the transcriptional profiles of oncogenic *Kras*-expressing cells with or without *Wt1* expression were analyzed (3). The authors reasoned that if *WT1* targets were indeed important for *RAS*-induced tumorigenesis, it would be expected that patients with activated *RAS* alleles and decreased expression of *WT1* target genes would have an improved prognosis. The transcriptional profiles obtained from the MEFs were used to develop “*WT1* high” and “*WT1* low” signatures. Using these signatures, the authors showed that the *WT1*-signature status allowed stratification of lung cancer patients into poor and good prognosis groups, but only in the presence of a contemporaneous *KRAS* gene signature. This suggests that *WT1* modulates expression of genes that are specifically relevant to *KRAS*-driven lung cancers. While the data are highly circumstantial, they support the notion of a *KRAS/WT1* synthetic-lethal interaction in patients. Clearly, additional studies are required to further explore this hypothesis.

Senescence and the anticancer barrier

How does the status of *Wt1* so profoundly have an impact on cells harboring an activating *Kras* mutation? Vicent et al. show that the loss of *Wt1* expression in the context of activated *Kras* in MEFs results in decreased cellular proliferation and increased senescence (3). Importantly, they corroborated these observations, made in primary MEFs and in mouse lung tumor cells, in human NSCLC cell lines (Table 1). *Kras* represents the paradigm of oncogene-induced senescence (OIS), being the first oncogene for which

paradoxical growth arrest after ectopic expression was observed (14). Work over the past few years has suggested that the ability of oncogenic *Kras* to induce senescence versus proliferation depends on the levels of its expression above a certain threshold (15, 16). In addition, it has been recently proposed that induction of senescence and resistance to oncogenic *Kras* transformation is tissue specific and correlates with the strength of tumor suppression, as assessed by the transcriptional status of the *p19Arf* locus (17). In this study, Young and Jacks show that physiological levels of oncogenic *Kras* expression induce transformation rather than senescence in the lung due to a stable transcriptional silencing of the *p19Arf* locus, whereas in other tissues, where this locus is in a more permissive state, expression of oncogenic *Kras* strongly induces *p19Arf* expression and consequently the onset of the senescence response.

The question of how *Wt1* controls senescence remains open (neither alterations in the levels of *p16Ink4a*, *p19Arf*, and *trp53* expression nor increased activation of downstream MAPK signaling was found by Vicent et al. after knockdown of *Wt1* expression) (3). Nevertheless, the data from Vicent et al. are of significant interest because they demonstrate that in mouse primary cells, under certain conditions such as *Wt1* loss, senescence can occur in response to physiologic levels of oncogenic *Kras*. These observations also point to the involvement of what could potentially be a novel tumor suppressive mechanism that likely does not involve the usual suspects previously implicated in control of senescence.

Future directions

While a number of studies have recently pointed at OIS, originally identified as an in vitro phenomenon, as a barrier to tumorigenesis in vivo, the mechanistic



details involved in the process remain incompletely understood (18–21). An interesting question stemming from the work of Vicent et al. (3) is whether their observations regarding senescence also occur in vivo. The authors show that deletion of *Wt1* in the context of oncogenic Kras in the lung results in a significant reduction in tumor volume but not in the total number of lesions, indicating that *Wt1* loss likely affects tumor progression rather than initiation. This fits with a role for *Wt1* in repressing the senescence response to oncogenic Kras as observed in vitro. However, more studies are needed to conclusively prove that *Wt1* controls Kras-induced senescence in vivo.

Acknowledgments

The work in the Kissil laboratory is supported in part by NIH grant R01CA124495 and the American Cancer Society.

Address correspondence to: Joseph L. Kissil, Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadel-

phia, Pennsylvania 19104, USA. Phone: 215.898.3874; Fax: 215.898.3572; E-mail: jkissil@wistar.org.

1. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. *Nat Rev Mol Cell Biol*. 2008;9(7):517–531.
2. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. *Nat Rev Cancer*. 2005;5(9):689–698.
3. Vicent S, et al. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. *J Clin Invest*. 2010; 120(11):3940–3952.
4. Westbrook TF, Stegmeier F, Elledge SJ. Dissecting cancer pathways and vulnerabilities with RNAi. *Cold Spring Harb Symp Quant Biol*. 2005;70:435–444.
5. Downward J. Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells. *Oncogene*. 2004;23(51):8376–8383.
6. Bernards R, Brummelkamp TR, Beijersbergen RL. shRNA libraries and their use in cancer genetics. *Nat Methods*. 2006;3(9):701–706.
7. Sharma S, Rao A. RNAi screening: tips and techniques. *Nat Immunol*. 2009;10(8):799–804.
8. Barbie DA, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. *Nature*. 2009;462(7269):108–112.
9. Luo J, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. *Cell*. 2009;137(5):835–848.
10. Scholl C, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. *Cell*. 2009;137(5):821–834.

11. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. *Sci STKE*. 2006; 2006(357):re13.
12. Rivera MN, Haber DA. Wilms' tumour: connecting tumorigenesis and organ development in the kidney. *Nat Rev Cancer*. 2005;5(9):699–712.
13. Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. *Leukemia*. 2007;21(5):868–876.
14. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell*. 1997;88(5):593–602.
15. Tuveson DA, et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. *Cancer Cell*. 2004;5(4):375–387.
16. DeNicola GM, Tuveson DA. RAS in cellular transformation and senescence. *Eur J Cancer*. 2009;45(Suppl 1):211–216.
17. Young NP, Jacks T. Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. *Proc Natl Acad Sci U S A*. 2010;107(22):10184–10189.
18. Braig M, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. *Nature*. 2005;436(7051):660–665.
19. Chen Z, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. *Nature*. 2005;436(7051):725–730.
20. Collado M, et al. Tumour biology: senescence in premalignant tumours. *Nature*. 2005;436(7051):642.
21. Michaloglou C, et al. BRAF600-associated senescence-like cell cycle arrest of human naevi. *Nature*. 2005;436(7051):720–724.

Are there more tricks in the bag for treating thrombocytopenia?

Andrew D. Leavitt

Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA.

Thrombocytopenia, an abnormally low number of circulating platelets, results from inadequate platelet production, splenic platelet sequestration, or accelerated platelet clearance. Platelet transfusions are now the cornerstone for treating thrombocytopenia. With an ever-expanding demand for platelets, and with many patients having an inadequate response to platelet transfusions, new strategies are needed to treat thrombocytopenia. In this issue of the JCI, Fuentes et al. present provocative data regarding the use of direct megakaryocyte infusions as a novel approach to manage this vexing clinical problem.

It was only 100 years ago that James Wright reported that his modification of the Romanowsky stain could unequivocally identify platelets on a peripheral blood smear (1). Applying his new stain and careful observations to bone marrow specimens, in 1910 Wright proposed that “the blood platelets are detached portions

or fragments of the cytoplasm of the megakaryocytes, which are in such relation to the blood channels in the marrow that detached portions of their cytoplasm are quickly carried by the blood current into the circulation. The breaking up of the cytoplasm into the platelets occurs only in cells which have reached a certain stage of growth and development, and is probably rapidly completed when once begun. It takes place in various ways but usually by the pinching off of small rounded projections or pseudopods from the cell body

or from larger pseudopods, or by the segmentation of slender pseudopods, or by the pinching off of longer or shorter pseudopods which may or may not undergo segmentation later” (2).

Data accumulated over the past 10 years strongly suggest that platelets emerge from the tips of “proplatelets,” the long cytoplasmic extensions generated by large, mature, polyploid megakaryocytes (Figure 1). Proplatelet extensions are produced by anti-parallel microtubule sliding powered by dynein motors, and repeated branching increases the number of platelet-releasing ends (3). Platelet granules and organelles are manufactured in the megakaryocyte cell body, transported down the extensions by kinesin motors, and then packaged into budding platelets (3). The proplatelet ends uniquely contain a marginal microtubule coil similar to that seen in mature platelets, supporting the idea that platelets are released from proplatelet tips and helping explain the biologi-

Conflict of interest: The author has declared that no conflict of interest exists.

Citation for this article: *J Clin Invest*. 2010; 120(11):3807–3810. doi:10.1172/JCI45179.